Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems?

Journal of Pharmaceutical Sciences

Volumn 96, Issue 3, 2007, Pages 473-483

  Illum, Lisbeth ^a  

^a IDentity   (United Kingdom)

Author keywords

Chitosan; Drug delivery; Nanoparticles; Nasal; PLA PEG; Vaccine delivery

Indexed keywords

CHITOSAN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INSULIN; LECTIN; MACROGOL; NANOPARTICLE; PEPTIDE DERIVATIVE; POLYSTYRENE; PROTEIN DERIVATIVE; TETANUS TOXOID; VACCINE;

ANTIBODY RESPONSE; AREA UNDER THE CURVE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG TRANSPORT; EVIDENCE BASED MEDICINE; HUMAN; IMMUNE RESPONSE; LYMPHOID TISSUE; NONHUMAN; NOSE CAVITY; NOSE MUCOSA; OLFACTORY EPITHELIUM; PARTICLE SIZE; POWDER; RABBIT; RESPIRATORY EPITHELIUM; REVIEW; SHEEP; SURFACE PROPERTY; TETANUS;

EID: 33947529032     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20718     Document Type: Review

References (49)

1. Donovan MD, Huang Y. 1998. Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Del Rev 29: 147-155
2. Dyer AM, Hinchcliffe M, Watts P, Castile J, Jabbal-Gill I, Nankervis R, Smith A, Illum L. 2002. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm Res 19:998-1008.
3. Cui Z, Mumper RJ. 2002. Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses. J Pharm Pharmacol 54:1195-1203.
4. Lemarchand C, Gref R, Couvreur P. 2004. Polysachharide-decorated nanoparticles. Eur J Pharm Biopharm 58:327-341.
5. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, Alonso MJ. 2004. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur J Pharm Biopharm 57:123-131.
6. Fernandez-Urrusuno R, Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. 1999. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 16:1576-1581.
7. Betbeder D, Sperandio S, Latapie J-P, de Nadai J, Etienne A, Zajac J-M, Frances B. 2000. BiovectorTM nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm Res 17:743-748.
8. Janes KA, Calvo P, Alonso MJ. 2001. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Del Rev 47:83-97.
9. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. 2002. Design of biodegradable particles for protein delivery. J Control Rel 78:15-24.
10. Nagamoto T, Hattori Y, Takayama K, Maitani Y. 2004. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 21:671-674.
11. Illum L. 2004. Is nose-to-brain transport of drugs in man a reality ? J Pharm Pharmacol 56:3-17.
12. Madara JL. 2000. Modulation of tight junctional permeability. Adv Drug Del Rev 41:251-253.
13. Hayashi M, Hirasawa T, Muraoka T, Shiga M, Awaza S. 1985. Comparison of water influx and sieving coefficient in rat jejunal, rectal and nasal absorption of antipyrine. Chem Pharm Bull 33: 2149-2152.
14. Ward PD, Tippin TK, Thakker DR. 2000. Enhancing paracellular permeability by modulating epithelial tight junctions. PSIT 3:346-358.
15. Tsukamoto T, Nigam SK. 1999. Role of tyrosine phosphorylation in the reassembly of occludin and other tight junction proteins. Am J Physiol 276: F737-F750.
16. Smith JM, Dornish M, Wood EJ. 2005. Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption. Biomaterials 26:3269-3276.
17. Frieke Kuper C, Koornstra PJ, Hameleers DMH, Biewenga J, Spit BJ, Duijvestijn AM, van Breda Vriesman PJC, Sminia T. 1992. The role of nasopharyngeal lymphoid tissue. Immunol Today 13:219-224.
18. Behrens I, Vila Pena AI, Alonso MJ, Kissel T. 2002. Comparative uptake studies of bioadhesive nanoparticles in human intestinal cell lines and rats: The effect of mucus on particle adsorption and transport. Pharm Res 19:1185-1193.
19. Florence AT, Hillery AM, Hussain N, Jani PU. 1995. Factors affecting the oral uptake and translocation of polystyrene nanoparticles: Histological and analytical evidence. J Drug Target 3:65-70.
20. Almeida AJ, Alpar HO, Brown MRW. 1993. Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and gunea pigs. J Pharm Pharmacol 45:198-203.
21. Huang Y, Donovan MD. 1996. Microspheres transport pathways in the rabbit nasal mucosa. Int J Pharm Adv 1:298-309.
22. Brooking J, Davis SS, Illum L. 2001. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9:267-279.
23. Tobia M, Gref R, Sanchez A, Langer R, Alonso MJ. 1998. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15: 270-275.
24. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ. 2005. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 292:43-52.
25. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ. 1999. Development of a freeze dried formulation of insulin-loaded chitosan nanoparticles intended for nasal administration. S.T.P Pharma Sci 9:429-436.
26. Mao S, Germershaus O, Fischer D, Linn T, Schnepf R, Kissel T. 2005. Uptake and transport of PEG-graft-trimethyl-chitosan copolymer-insulin nanocomplexes by epithelial cells. Pharm Res 22: 2058-2068.
27. Simon M, Wittmar M, Kissel T, Linn T. 2005. Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(L-lactide): Bioavailability and nasal tolerability in rats. Pharm Res 22:1879-1886.
28. Kravtzoff R, Fisher A, de Miguel I, Perkins A, Major M, Betbeder D, anf Etienne A. 1998. Nasal residence time evaluation of cationic biovectorTM in human volunteers. Proc Int Symp Control Rel Bioact Mater 25:818-819
29. Oberdörster G, Sharp Z, Atudorei V, Elder A, Gelein R, Kreyling WC. 2004. Translocation of inhaled ultrafine particles to the brain. Inhal Toxicol 16:437-445.
30. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, Fu S. 2006. Lectin-conjugated PEG-PLA nanoparticles: Preparation and brain delivery after intranasal administration. Biomaterials 27:3482-3490.
31. Jung T, Kamm W, Breitenbach A, Hungerer K-L, Hundt E, Kissel T. 2001. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): Evaluation of antibody response after oral and nasal application in mice. Pharm Res 18:352-360.
32. Debin A, Kravtzoff R, Vaz Santiago J, Cazales L, Sperandino S, Melber K, Janowics Z, Betbeder D, Moynier M. 2002. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20: 2752-2763.
33. Calvo P, Remunan-Lopez C, Vila Jato JL, Alonso MJ. 1997. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm Res 14:1431-1436.
34. Calvo P, Remunan-Lopez C, Vila Jato JL, Alonso MJ. 1997. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Poly Sci 63:125-132.
35. Vila A, Sanchez A, Evora C, Soriano I, Vila Jato JL, Alonso MJ. 2004. PEG-PLA nanoparticles as carriers for nasal vaccine delivery. J Aerosol Med 17:174-185.
36. Hillery AM, Florence AT. 1996. The effect of absorbed poloxamer 188 and 407 surfactants on the intestinal uptake of 60 nm polystyrene particles after oral administration in the rats. Int J Pharm 132:123-130.
37. Stolnik S, Heal CR, Garnett MG, Illum L, Davis SS. 2005. Differences in the adsorption behaviour of poly(ethylene oxide) copolymers onto model colloidal drug carrier assessed by isothermal titration microcalorimetry J Drug Target 13:449-458.
38. Vila A, Gill H, McCallion O, Alonson MJ. 2004. Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Rel 98:231-244.
39. Tobio M, Sanchez A, Vila A, Soriano I, Evora C, Vila-Jato JL, Alonso MJ. 2000. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces 18:315-323.
40. Artursson P, Lindmark T, Davis SS, Illum L. 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11:1358-1361.
41. Prego C, Garcia M, Torres D, Alonson MJ. 2005. Transmucosal macromolecular drug delivery. J Control Rel 101:151-162.
42. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. 2006. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Rel 111:107-116.
43. Eyles JE, Bramwell VW, Williamson ED, Alpar HO. 2001. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19:4732-4742.
44. Carr RE, Lolachi CM, Albaran RG, Ridley DM, Montgomery PC, O'Sullivan NL. 1996. Nasal associated lymphoid tissue is an inductive site for rat tear IgA responses. Immunol Invest 25:387-396.
45. Ghirardelli R, Bonasoro F, Porta C, Cremaschi D. 1999. Identification of particular epithelial areas and cells that transport polypeptide-coated nanoparticles in the nasal respiratory mucosa of the rabbit. Biochim Biophys Acta 1416:39-47.
46. The Royal Society. 2004. Nanoscience and nanotechnologies: Opportunities and uncertainties. Chapter 5. Possible adverse health, environmental and safety aspects. www.royalsoc.ac.uk.
47. Auger F, Gendron MC, Chamot C, Marano F, Dazy AC. 2006. Response of well-differentiated nasal epithelial cells exposed to particles: Role of the epithelial in airway inflammation. Toxicol Appl Pharmacol April 26 (Epub ahead of print).
48. Gonda I, Gipps E. 1990. Model of disposition of drugs administered into the human nasal cavity. Pharm Res 7:69-75.
49. Gonda I. 1998. Mathematical modeling of deposition and disposition of drugs administered via the nose. Adv Drug Del Rev 29:179-184.